Market closed
Vericel/$VCEL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vericel
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Ticker
$VCEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
-
Website
Vericel Metrics
BasicAdvanced
$2.8B
Market cap
785.48
P/E ratio
$0.07
EPS
1.67
Beta
-
Dividend rate
Price and volume
Market cap
$2.8B
Beta
1.67
52-week high
$58.18
52-week low
$32.31
Average daily volume
419K
Financial strength
Current ratio
4.608
Quick ratio
3.633
Long term debt to equity
35.477
Total debt to equity
37.854
Interest coverage (TTM)
-2.00%
Management effectiveness
Return on assets (TTM)
-0.22%
Return on equity (TTM)
1.54%
Valuation
Price to earnings (TTM)
785.48
Price to revenue (TTM)
12.285
Price to book
11.01
Price to tangible book (TTM)
11.29
Price to free cash flow (TTM)
-231.948
Growth
Revenue change (TTM)
22.48%
Earnings per share change (TTM)
-133.92%
3-year revenue growth (CAGR)
13.82%
3-year earnings per share growth (CAGR)
150.97%
What the Analysts think about Vericel
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Vericel Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vericel Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vericel News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vericel stock?
Vericel (VCEL) has a market cap of $2.8B as of December 12, 2024.
What is the P/E ratio for Vericel stock?
The price to earnings (P/E) ratio for Vericel (VCEL) stock is 785.48 as of December 12, 2024.
Does Vericel stock pay dividends?
No, Vericel (VCEL) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Vericel dividend payment date?
Vericel (VCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Vericel?
Vericel (VCEL) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.